Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinosarcoma × pamiparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Gynecologic 1

Conditions

Ovarian Neoplasms 5 Neoplasms 3 Glioblastoma 3 Squamous Cell Carcinoma of Head and Neck 1 Rare Tumour 1 Neoadjuvant Therapy 1 Metastatic Castration-resistant Prostate Cancer 1 Locally Advanced Prostate Cancer 1 Limited Stage Small Cell Lung Cancer 1 Hereditary leiomyomatosis and renal cell cancer 1 Head and Neck Neoplasms 1 Glioma 1 Carcinosarcoma 1 Carcinoma, Renal Cell 1 Carcinoma, Ovarian Epithelial 1 Advanced Malignant Solid Neoplasm 1

Interventions

Specimen Handling 3 Paclitaxel 3 Nivolumab 3 olaparib 2 X-Rays 2 Carboplatin 2 Biopsy 2 sargramostim 1 pembrolizumab 1 pazopanib 1 pamiparib 1 durvalumab 1 ceralasertib 1 cediranib 1 atezolizumab 1 apatinib 1 Trabectedin 1 Tissue Banks 1 TIC10 compound 1 Minimally Invasive Surgical Procedures 1 Magnetic Resonance Spectroscopy 1 LY-2157299 1 Indocyanine Green 1 Immunoglobulin G 1 Gemcitabine 1 Cyclophosphamide 1 Colony-Stimulating Factors 1 Cisplatin 1 Blood Specimen Collection 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03933761 2021-08-10

PRECISE

Australia New Zealand Gynaecological Oncology Group

Phase 2 Withdrawn

GynecologicSarcoma

Carcinosarcoma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡